Safe Cosmetics and Personal Care Products Act of 2018

HOUSE AND SENATE APPROPRIATIONS The Breast Cancer Prevention Partners contacted House and Senate offices about increasing federal funding for the following: Centers for Disease Control and Prevention Programs, National Environmental Public Health Tracking Network Centers for Disease Control and Prevention Programs, Environmental Health Labs Biomonitoring Program National Institute of Environmental Health Sciences (NIEHS) The Breast Cancer Prevention Partners contacted Senate offices about preserving the current Design for the Environment program in the EPA. CURRENT LEGISLATIVE PROPOSALS: The Breast Cancer Prevention Partners supports H.R. 2728, the Cleaning Product Labeling Act of 2017, which would require the disclosure of ingredients in cleaning products. The Breast Cancer Prevention Partners supports reform and strengthening of the personal care products regulatory system, and is working to ensure strong, health protective measures are included in legislation such as S.1113, the Personal Care Products Safety Act, and any other legislation that would impact the safety of personal care products including H.R. 6903, the Safe Cosmetics and Personal Care Products Act of 2018. Breast Cancer Prevention Partners opposes the Accurate Labels Act (S.3019, H.R.6022) because it undermines transparency for consumers and undermines states' ability to protect the public health of their citizens by preempting science-based ingredient labeling for consumer goods. FUTURE LEGISLATIVE PROPOSALS: The Breast Cancer Prevention Partners visits Senate offices to support an amendment to the Senate NDAA that directs the Secretary of Defense, in carrying out research, development, test, and evaluation activities with respect to breast cancer, to implement the recommendations of the Interagency Breast Cancer and Environmental Research Coordinating Committee to prioritize prevention and increase the study of chemical and physical factors in breast cancer (IBCERCC). The Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. The Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. The Breast Cancer Prevention Partners supports actions to ensure appropriate definition and regulation of chemicals Generally Recognized as Safe (GRAS). REGULATION AND LEGISLATIVE INTENT: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), the Breast Cancer Prevention Partners has also met with members of the FDA management team concerning the FDAs ongoing cosmetics regulation negotiations and the FDAs transparency policies more generally. P.L. 110-314 - The Consumer Product Safety Commission Improvement Act The Breast Cancer Prevention Partners lobbied in support of the provision that bans the use of phthalates in the manufacture of childrens toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and urging expeditious research and regulatory action as required by the legislation. P.L. 114-182 - The Frank R. Lautenberg Chemical Safety for the 21st Century Act The Breast Cancer Prevention Partners is working to support and encourage strong, health-protective implementation of the recently- enacted reform of the Toxic Substances Control Act (TSCA).

Client expense: Not reported · Firm income: $10,000

Government targets: Consumer Product Safety Commission (CPSC), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE

HOUSE AND SENATE APPROPRIATIONS The Breast Cancer Prevention Partners contacted House and Senate offices about increasing federal funding for the following: Centers for Disease Control and Prevention Programs, National Environmental Public Health Tracking Network Centers for Disease Control and Prevention Programs, Environmental Health Labs Biomonitoring Program National Institute of Environmental Health Sciences (NIEHS) The Breast Cancer Prevention Partners contacted Senate offices about preserving the current Design for the Environment program in the EPA. CURRENT LEGISLATIVE PROPOSALS: The Breast Cancer Prevention Partners supports H.R. 2728, the Cleaning Product Labeling Act of 2017, which would require the disclosure of ingredients in cleaning products. The Breast Cancer Prevention Partners supports reform and strengthening of the personal care products regulatory system, and is working to ensure strong, health protective measures are included in legislation such as S.1113, the Personal Care Products Safety Act, and any other legislation that would impact the safety of personal care products including H.R. 6903, the Safe Cosmetics and Personal Care Products Act of 2018. Breast Cancer Prevention Partners opposes the Accurate Labels Act (S.3019, H.R.6022) because it undermines transparency for consumers and undermines states' ability to protect the public health of their citizens by preempting science-based ingredient labeling for consumer goods. FUTURE LEGISLATIVE PROPOSALS: The Breast Cancer Prevention Partners visits Senate offices to support an amendment to the Senate NDAA that directs the Secretary of Defense, in carrying out research, development, test, and evaluation activities with respect to breast cancer, to implement the recommendations of the Interagency Breast Cancer and Environmental Research Coordinating Committee to prioritize prevention and increase the study of chemical and physical factors in breast cancer (IBCERCC). The Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. The Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. The Breast Cancer Prevention Partners supports actions to ensure appropriate definition and regulation of chemicals Generally Recognized as Safe (GRAS). REGULATION AND LEGISLATIVE INTENT: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), the Breast Cancer Prevention Partners has also met with members of the FDA management team concerning the FDAs ongoing cosmetics regulation negotiations and the FDAs transparency policies more generally. P.L. 110-314 - The Consumer Product Safety Commission Improvement Act The Breast Cancer Prevention Partners lobbied in support of the provision that bans the use of phthalates in the manufacture of childrens toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and urging expeditious research and regulatory action as required by the legislation. P.L. 114-182 - The Frank R. Lautenberg Chemical Safety for the 21st Century Act The Breast Cancer Prevention Partners is working to support and encourage strong, health-protective implementation of the recently- enacted reform of the Toxic Substances Control Act (TSCA).

HOUSE AND SENATE APPROPRIATIONS The Breast Cancer Prevention Partners contacted House and Senate offices about increasing federal funding for the following: Centers for Disease Control and Prevention Programs, National Environmental Public Health Tracking Network Centers for Disease Control and Prevention Programs, Environmental Health Labs Biomonitoring Program National Institute of Environmental Health Sciences (NIEHS) The Breast Cancer Prevention Partners contacted Senate offices about preserving the current Design for the Environment program in the EPA. CURRENT LEGISLATIVE PROPOSALS: The Breast Cancer Prevention Partners supports H.R. 2728, the Cleaning Product Labeling Act of 2017, which would require the disclosure of ingredients in cleaning products. The Breast Cancer Prevention Partners supports reform and strengthening of the personal care products regulatory system, and is working to ensure strong, health protective measures are included in legislation such as S.1113, the Personal Care Products Safety Act, and any other legislation that would impact the safety of personal care products including H.R. 6903, the Safe Cosmetics and Personal Care Products Act of 2018. Breast Cancer Prevention Partners opposes the Accurate Labels Act (S.3019, H.R.6022) because it undermines transparency for consumers and undermines states' ability to protect the public health of their citizens by preempting science-based ingredient labeling for consumer goods. FUTURE LEGISLATIVE PROPOSALS: The Breast Cancer Prevention Partners visits Senate offices to support an amendment to the Senate NDAA that directs the Secretary of Defense, in carrying out research, development, test, and evaluation activities with respect to breast cancer, to implement the recommendations of the Interagency Breast Cancer and Environmental Research Coordinating Committee to prioritize prevention and increase the study of chemical and physical factors in breast cancer (IBCERCC). The Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. The Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. The Breast Cancer Prevention Partners supports actions to ensure appropriate definition and regulation of chemicals Generally Recognized as Safe (GRAS). REGULATION AND LEGISLATIVE INTENT: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), the Breast Cancer Prevention Partners has also met with members of the FDA management team concerning the FDAs ongoing cosmetics regulation negotiations and the FDAs transparency policies more generally. P.L. 110-314 - The Consumer Product Safety Commission Improvement Act The Breast Cancer Prevention Partners lobbied in support of the provision that bans the use of phthalates in the manufacture of childrens toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and urging expeditious research and regulatory action as required by the legislation. P.L. 114-182 - The Frank R. Lautenberg Chemical Safety for the 21st Century Act The Breast Cancer Prevention Partners is working to support and encourage strong, health-protective implementation of the recently- enacted reform of the Toxic Substances Control Act (TSCA).

OTC Drug Review Monograph H.R. 5333/S.2315 - Over-the-Counter Drug Safety, Innovation, and Reform Act. Legislation to update and modernize the Over-the-Counter Drug Review Monograph system, which regulates the manufacture, labeling, and marketing of specific over-the-counter (OTC) drugs. H.R. 7328 - Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 H.R.6903 - Safe Cosmetics and Personal Care Products Act of 2018

Client expense: $197,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of

H.R. 906 (Furthering Asbestos Claims Transparency Act); amends title 11 of the United States Code to require the public disclosure by trusts established under section 524(g) of such title, of quarterly reports that contain detailed information regarding the receipt and disposition of claims for injuries based on exposure to asbestos. H.R. 1563 (Mary Jo Lawyer Spano Mesothelioma Patient Registry Act of 2017); amends the Public Health Service Act to provide for the establishment of a mesothelioma patient registry. H.R. 575 (Cosmetic Modernization Amendments of 2017); amends the Federal Food, Drug, and Cosmetic Act to establish new procedures and requirements for the registration of cosmetic manufacturing establishments, the submission of cosmetic and ingredient statements, and the reporting of serious cosmetic adverse events. S. 1113 (Personal Care Products Safety Act); amends the Federal Food, Drug, and Cosmetic Act to ensure the safety of cosmetics. H.R. 832 (Arbitration Transparency Act); amends title 9 of the United States Code to require that arbitration proceedings in certain disputes involving consumer financial products and services be open to the public. S. 542 (Safety Over Arbitration Act of 2017); amends title 9, United States Code, with respect to arbitration where the claim or controversy alleges facts relevant to a hazard to public health or safety. S. 552/H.R. 1414 (Justice for Victims of Fraud Act); amends the Truth in Lending Act and the Electronic Fund Transfer Act to provide justice to victims of fraud. S. 550/H.R. 1396 (Restoring Statutory Rights Act); invalidates arbitration agreements between parties in certain commercial contracts or transactions if they require arbitration of a claim for damages or injunctive relief brought by an individual or small business arising from the alleged violation of a federal or state statute, the U.S. Constitution, or a state constitution. S. 646/H.R. 2631 (Justice for Servicemembers and Veterans Act); amends title 38, United States Code, to improve the enforcement of employment and reemployment rights of members of the uniformed services, to amend the Servicemembers Civil Relief Act to improve the protection of members of the uniformed services. S. 647 (Mandatory Arbitration Transparency Act); amends title 9, United States Code, with respect to arbitration. S. 537/H.R. 1374 (Arbitration Fairness Act); prohibits mandatory, pre-dispute arbitration in employment, consumer, antitrust, or civil rights disputes. S. 2203/H.R. 4734/H.R. 4570 (Ending Forced Arbitration of Sexual Harassment Act of 2017); prohibits a pre-dispute arbitration agreement from being valid or enforceable if it requires arbitration of a sex discrimination dispute. H.R. 3857 (PASS Act of 2017); amend the Securities Exchange Act of 1934 to lower standards of conduct for brokers and dealers that are in the best interest of their retail customers. S. 534/H.R. 1973 (Protecting Young Victims from Sexual Abuse Act of 2017); prevents the sexual abuse of minors and amateur athletes by requiring the prompt reporting of sexual abuse to law enforcement authorities S. 2564, (PROTECT Asbestos Victims Act of 2018); restricts claims against asbestos trusts and provides for criminal penalties for fraudulent claims. S. 1112, (Maternal Health Accountability Act of 2017); retricts the use of information reviewed by the maternal mortality review committee. Infomration is considered confidential and not subject to dioscvery at a civil trial. S. 2852 (Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018); regarding immunity provisions. H.R. 6022/ S. 3019 (Accurate Labels Act); regarding the broad preemption of state and local labeling laws for consumer products. H.R. 6903 (Safe Cosmetics and Personal Care Products Act of 2018); amends current law to ensure the safety of cosmetics and personal care products. H.R. 919 (Blitz Gas Can bill). General issues pertaining to Asbestos Bankruptcy Trusts. Cosmetic Regulation and Safety and realted preemption issues in Murray Alexander draft bill. General lobbying with regard to the Education Departments borrower defenses rule. General lobbying with regard to warranties of Energy Star-rated products and ability of consumers to bring a class action against manufacturers of Energy Star-rated products. General lobbying with regard to pesticide regulations. General lobbying with regard to amending Telephone Consumer Protection Act liability. General lobbying with regard to attorney advertising issues. General lobbying with regard to asbestos exposure and related health and environmental issues. General lobbying with regard to liability issues related to regulation of cosmetics products. General lobbying with regard to TSCA implementation.

Legislation relating to chemical safety, cosmetic ingredients safety, and disclosure of fragrance ingredients in consumer products S. 1113 (Personal Care Products Safety Act), all provisions S. 2003 (FDA Cosmetic Safety and Modernization Act), all provisions H.R.575 (Cosmetic Modernization Amendments of 2017), all provisions H.R. 4964 (Children's Product Warning Label Act of 2018), all provisions H.R. 6903 (Safe Cosmetics and Personal Care Products Act of 2018), all provisions Formation of Congressional Fragrance Caucus

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Legislation relating to Cosmetics Reform (chemical safety, cosmetic ingredient safety, and disclosure of fragrance ingredients in consumer products). HR 575; S 1113; S 2003; HR 4964; HR 6903, all provisions. Formation of Congressional Fragrance Caucus.

Client expense: $80,000 · Firm income: Not reported

Government targets: Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE

HOUSE AND SENATE APPROPRIATIONS The Breast Cancer Prevention Partners contacted House and Senate offices about increasing federal funding for the following: Centers for Disease Control and Prevention Programs, National Environmental Public Health Tracking Network Centers for Disease Control and Prevention Programs, Environmental Health Labs Biomonitoring Program National Institute of Environmental Health Sciences (NIEHS) The Breast Cancer Prevention Partners contacted Senate offices about preserving the current Design for the Environment program in the EPA. CURRENT LEGISLATIVE PROPOSALS: The Breast Cancer Prevention Partners supports H.R. 2728, the Cleaning Product Labeling Act of 2017, which would require the disclosure of ingredients in cleaning products. The Breast Cancer Prevention Partners supports reform and strengthening of the personal care products regulatory system, and is working to ensure strong, health protective measures are included in legislation such as S.1113, the Personal Care Products Safety Act, and any other legislation that would impact the safety of personal care products including H.R. 6903, the Safe Cosmetics and Personal Care Products Act of 2018. Breast Cancer Prevention Partners opposes the Accurate Labels Act (S.3019, H.R.6022) because it undermines transparency for consumers and undermines states' ability to protect the public health of their citizens by preempting science-based ingredient labeling for consumer goods. FUTURE LEGISLATIVE PROPOSALS: The Breast Cancer Prevention Partners visits Senate offices to support an amendment to the Senate NDAA that directs the Secretary of Defense, in carrying out research, development, test, and evaluation activities with respect to breast cancer, to implement the recommendations of the Interagency Breast Cancer and Environmental Research Coordinating Committee to prioritize prevention and increase the study of chemical and physical factors in breast cancer (IBCERCC). The Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. The Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. The Breast Cancer Prevention Partners supports actions to ensure appropriate definition and regulation of chemicals Generally Recognized as Safe (GRAS). REGULATION AND LEGISLATIVE INTENT: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), the Breast Cancer Prevention Partners has also met with members of the FDA management team concerning the FDAs ongoing cosmetics regulation negotiations and the FDAs transparency policies more generally. P.L. 110-314 - The Consumer Product Safety Commission Improvement Act The Breast Cancer Prevention Partners lobbied in support of the provision that bans the use of phthalates in the manufacture of childrens toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and urging expeditious research and regulatory action as required by the legislation. P.L. 114-182 - The Frank R. Lautenberg Chemical Safety for the 21st Century Act The Breast Cancer Prevention Partners is working to support and encourage strong, health-protective implementation of the recently- enacted reform of the Toxic Substances Control Act (TSCA).

HOUSE AND SENATE APPROPRIATIONS The Breast Cancer Prevention Partners contacted House and Senate offices about increasing federal funding for the following: Centers for Disease Control and Prevention Programs, National Environmental Public Health Tracking Network Centers for Disease Control and Prevention Programs, Environmental Health Labs Biomonitoring Program National Institute of Environmental Health Sciences (NIEHS) The Breast Cancer Prevention Partners contacted Senate offices about preserving the current Design for the Environment program in the EPA. CURRENT LEGISLATIVE PROPOSALS: The Breast Cancer Prevention Partners supports H.R. 2728, the Cleaning Product Labeling Act of 2017, which would require the disclosure of ingredients in cleaning products. The Breast Cancer Prevention Partners supports reform and strengthening of the personal care products regulatory system, and is working to ensure strong, health protective measures are included in legislation such as S.1113, the Personal Care Products Safety Act, and any other legislation that would impact the safety of personal care products including H.R. 6903, the Safe Cosmetics and Personal Care Products Act of 2018. Breast Cancer Prevention Partners opposes the Accurate Labels Act (S.3019, H.R.6022) because it undermines transparency for consumers and undermines states' ability to protect the public health of their citizens by preempting science-based ingredient labeling for consumer goods. FUTURE LEGISLATIVE PROPOSALS: The Breast Cancer Prevention Partners visits Senate offices to support an amendment to the Senate NDAA that directs the Secretary of Defense, in carrying out research, development, test, and evaluation activities with respect to breast cancer, to implement the recommendations of the Interagency Breast Cancer and Environmental Research Coordinating Committee to prioritize prevention and increase the study of chemical and physical factors in breast cancer (IBCERCC). The Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. The Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. The Breast Cancer Prevention Partners supports actions to ensure appropriate definition and regulation of chemicals Generally Recognized as Safe (GRAS). REGULATION AND LEGISLATIVE INTENT: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), the Breast Cancer Prevention Partners has also met with members of the FDA management team concerning the FDAs ongoing cosmetics regulation negotiations and the FDAs transparency policies more generally. P.L. 110-314 - The Consumer Product Safety Commission Improvement Act The Breast Cancer Prevention Partners lobbied in support of the provision that bans the use of phthalates in the manufacture of childrens toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and urging expeditious research and regulatory action as required by the legislation. P.L. 114-182 - The Frank R. Lautenberg Chemical Safety for the 21st Century Act The Breast Cancer Prevention Partners is working to support and encourage strong, health-protective implementation of the recently- enacted reform of the Toxic Substances Control Act (TSCA).

HOUSE AND SENATE APPROPRIATIONS The Breast Cancer Prevention Partners contacted House and Senate offices about increasing federal funding for the following: Centers for Disease Control and Prevention Programs, National Environmental Public Health Tracking Network Centers for Disease Control and Prevention Programs, Environmental Health Labs Biomonitoring Program National Institute of Environmental Health Sciences (NIEHS) The Breast Cancer Prevention Partners contacted Senate offices about preserving the current Design for the Environment program in the EPA. CURRENT LEGISLATIVE PROPOSALS: The Breast Cancer Prevention Partners supports H.R. 2728, the Cleaning Product Labeling Act of 2017, which would require the disclosure of ingredients in cleaning products. The Breast Cancer Prevention Partners supports reform and strengthening of the personal care products regulatory system, and is working to ensure strong, health protective measures are included in legislation such as S.1113, the Personal Care Products Safety Act, and any other legislation that would impact the safety of personal care products including H.R. 6903, the Safe Cosmetics and Personal Care Products Act of 2018. Breast Cancer Prevention Partners opposes the Accurate Labels Act (S.3019, H.R.6022) because it undermines transparency for consumers and undermines states' ability to protect the public health of their citizens by preempting science-based ingredient labeling for consumer goods. FUTURE LEGISLATIVE PROPOSALS: The Breast Cancer Prevention Partners visits Senate offices to support an amendment to the Senate NDAA that directs the Secretary of Defense, in carrying out research, development, test, and evaluation activities with respect to breast cancer, to implement the recommendations of the Interagency Breast Cancer and Environmental Research Coordinating Committee to prioritize prevention and increase the study of chemical and physical factors in breast cancer (IBCERCC). The Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. The Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. The Breast Cancer Prevention Partners supports actions to ensure appropriate definition and regulation of chemicals Generally Recognized as Safe (GRAS). REGULATION AND LEGISLATIVE INTENT: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), the Breast Cancer Prevention Partners has also met with members of the FDA management team concerning the FDAs ongoing cosmetics regulation negotiations and the FDAs transparency policies more generally. P.L. 110-314 - The Consumer Product Safety Commission Improvement Act The Breast Cancer Prevention Partners lobbied in support of the provision that bans the use of phthalates in the manufacture of childrens toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and urging expeditious research and regulatory action as required by the legislation. P.L. 114-182 - The Frank R. Lautenberg Chemical Safety for the 21st Century Act The Breast Cancer Prevention Partners is working to support and encourage strong, health-protective implementation of the recently- enacted reform of the Toxic Substances Control Act (TSCA).

HOUSE AND SENATE APPROPRIATIONS The Breast Cancer Prevention Partners contacted House and Senate offices about increasing federal funding for the following: Centers for Disease Control and Prevention Programs, National Environmental Public Health Tracking Network Centers for Disease Control and Prevention Programs, Environmental Health Labs Biomonitoring Program National Institute of Environmental Health Sciences (NIEHS) The Breast Cancer Prevention Partners contacted Senate offices about preserving the current Design for the Environment program in the EPA. CURRENT LEGISLATIVE PROPOSALS: The Breast Cancer Prevention Partners supports H.R. 2728, the Cleaning Product Labeling Act of 2017, which would require the disclosure of ingredients in cleaning products. The Breast Cancer Prevention Partners supports reform and strengthening of the personal care products regulatory system, and is working to ensure strong, health protective measures are included in legislation such as S.1113, the Personal Care Products Safety Act, and any other legislation that would impact the safety of personal care products including H.R. 6903, the Safe Cosmetics and Personal Care Products Act of 2018. Breast Cancer Prevention Partners opposes the Accurate Labels Act (S.3019, H.R.6022) because it undermines transparency for consumers and undermines states' ability to protect the public health of their citizens by preempting science-based ingredient labeling for consumer goods. FUTURE LEGISLATIVE PROPOSALS: The Breast Cancer Prevention Partners visits Senate offices to support an amendment to the Senate NDAA that directs the Secretary of Defense, in carrying out research, development, test, and evaluation activities with respect to breast cancer, to implement the recommendations of the Interagency Breast Cancer and Environmental Research Coordinating Committee to prioritize prevention and increase the study of chemical and physical factors in breast cancer (IBCERCC). The Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. The Breast Cancer Prevention Partners supports ongoing efforts to reintroduce legislation in the House that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. The Breast Cancer Prevention Partners supports actions to ensure appropriate definition and regulation of chemicals Generally Recognized as Safe (GRAS). REGULATION AND LEGISLATIVE INTENT: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), the Breast Cancer Prevention Partners has also met with members of the FDA management team concerning the FDAs ongoing cosmetics regulation negotiations and the FDAs transparency policies more generally. P.L. 110-314 - The Consumer Product Safety Commission Improvement Act The Breast Cancer Prevention Partners lobbied in support of the provision that bans the use of phthalates in the manufacture of childrens toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and urging expeditious research and regulatory action as required by the legislation. P.L. 114-182 - The Frank R. Lautenberg Chemical Safety for the 21st Century Act The Breast Cancer Prevention Partners is working to support and encourage strong, health-protective implementation of the recently- enacted reform of the Toxic Substances Control Act (TSCA).